Nipro Corporation has entered into a Contract Manufacturing Agreement with AstraZeneca K.K. for the fill and finish process of AstraZeneca's COVID-19 vaccine, "Vaxzevria™ intramuscular injection".
Lead Product(s): Recombinant ChAdOx1-S
Therapeutic Area: Infections and Infectious Diseases Product Name: Vaxzevria
Highest Development Status: Approved Product Type: Vaccine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 26, 2021